|Videos|September 29, 2016

Exercise and Cerebral Blood Flow

What happens when athletes stop training for 10 days? Dr. Lazzara discusses a study of resting cerebral blood flow in gray matter and the hippocampus.

In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara reports on a study examining resting cerebral blood flow in the hippocampus and gray matter. Twelve master athletes aged 50 years and over were asked to cease all training and vigorous physical activity for ten days. Measurements were taken before and immediately after this period with perfusion-weighted MRI.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

In-Person + Virtual Event

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

February 6, 2026

Exercise and Cerebral Blood Flow

Newsletter

Latest CME

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis

Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA

Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival

Newborn Screening for Duchenne: Clinical and Policy Implications